Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use
Key facts
- Who runs it
- InBios International, Inc.
- Where
- Birmingham, Boise, Miami, Midland, New York, Odessa, St Louis, and The Bronx, United StatesSee the 10 sites
- Trial code
- Status
- Completed
- People taking part
- 899 people enrolled
- Started
- 26 Dec 2024
- Ended
- 19 May 2025
- Type of study
- Observational
- Treatments tested
- COVID/Flu Detect™ Rapid Self-Test
- Record updated
- 22 May 2025
Who can take part
- Age
- 2 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Subjects must be at least 18 years of age, or at least 2 years of age and accompanied by parent or legal guardian
- Subjects must be willing and able to give informed consent or assent (as age-appropriate)
- Subjects must be able to read/speak English (or Spanish at specific sites) if subject is an adult, minor aged 14 years or older, or parent/guardian of a child subject aged 2 through 13 years
- Subjects must be currently exhibiting at least two of the following symptoms consistent with possible SARS-CoV-2 or influenza infection: fever or feeling feverish (in absence of documented fever), chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, nasal congestion or runny nose, nausea or vomiting, and/or diarrhea. Subjects must be within 5 days of symptoms onset at enrollment (the day that symptoms start is day 0)
Who cannot take part
- Subject was previously enrolled in this study
- Subject has received results of an influenza or COVID-19 test within the previous 5 days
- Subject has undergone a nasal wash or nasal aspirate procedure on day of enrollment
- Subject has an active nosebleed
Where in United States
- Cahaba ResearchBirmingham, United States
- ASR, LLCBoise, United States
- Medicus Health Research Group IncMiami, United States
- Eastside Research AssociatesMidland, United States
- Ichan School of Medicine at Mount Sinai, Department of Emergency MedicineNew York, United States
- ERA Health ResearchOdessa, United States
- Barnes-Jewish HospitalSt Louis, United States
- St. Louis Children's HospitalSt Louis, United States
- Washington University School of MedicineSt Louis, United States
- CHEAR Center LLCThe Bronx, United States
About the trial
What the trial wants to find out
The goal of this study is to evaluate the performance of the COVID/Flu Detect™ Rapid Self-Test when used in a home-like setting by lay users. The COVID/Flu Detect™ Rapid Self-Test is an investigational device intended for the qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B protein antigens in nasal swab samples. Participants who are aged two (2) years and older and have symptoms of respiratory illness consistent with SARS-CoV-2 and influenza infection may be enrolled. Participants will use the COVID/Flu Detect™ Rapid Self-Test to self-collect, self-test, and interpret the results. Participants will have a nasal swab sample collected by a healthcare provider for comparator testing by PCR tests for SARS-CoV-2, influenza A, and influenza B. Researchers will compare the results of the COVID/Flu Detect™ Rapid Self-Test obtained by the participants to results from the PCR comparator tests to evaluate performance.
Treatments tested
- COVID/Flu Detect™ Rapid Self-Test
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 22 May 2025